Thor Medical ASA (OSL:TRMED)

Thor Medical ASA Statistics

Total Valuation

OSL:TRMED has a market cap or net worth of NOK 1.23 billion. The enterprise value is 1.02 billion.

Market Cap	1.23B
Enterprise Value	1.02B

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

OSL:TRMED has 352.99 million shares outstanding. The number of shares has increased by 17.08% in one year.

Current Share Class	352.99M
Shares Outstanding	352.99M
Shares Change (YoY)	+17.08%
Shares Change (QoQ)	+30.71%
Owned by Insiders (%)	4.25%
Owned by Institutions (%)	4.67%
Float	116.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12,319.21
PB Ratio	2.60
P/TBV Ratio	6.16
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-17.25
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.69

Financial Position

The company has a current ratio of 8.87, with a Debt / Equity ratio of 0.02.

Current Ratio	8.87
Quick Ratio	8.78
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.12
Interest Coverage	-323.39

Financial Efficiency

Return on equity (ROE) is -16.06% and return on invested capital (ROIC) is -10.77%.

Return on Equity (ROE)	-16.06%
Return on Assets (ROA)	-9.08%
Return on Invested Capital (ROIC)	-10.77%
Return on Capital Employed (ROCE)	-12.01%
Revenue Per Employee	7,692
Profits Per Employee	-4.53M
Employee Count	9
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-2.53M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +154.02% in the last 52 weeks. The beta is 0.10, so OSL:TRMED's price volatility has been lower than the market average.

Beta (5Y)	0.10
52-Week Price Change	+154.02%
50-Day Moving Average	3.54
200-Day Moving Average	2.73
Relative Strength Index (RSI)	46.63
Average Volume (20 Days)	1,710,327

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OSL:TRMED had revenue of NOK 100,000 and -58.91 million in losses. Loss per share was -0.22.

Revenue	100,000
Gross Profit	100,000
Operating Income	-64.03M
Pretax Income	-61.44M
Net Income	-58.91M
EBITDA	-51.85M
EBIT	-64.03M
Loss Per Share	-0.22

Balance Sheet

The company has 224.40 million in cash and 8.70 million in debt, giving a net cash position of 215.70 million or 0.61 per share.

Cash & Cash Equivalents	224.40M
Total Debt	8.70M
Net Cash	215.70M
Net Cash Per Share	0.61
Equity (Book Value)	473.50M
Book Value Per Share	1.36
Working Capital	220.40M

Cash Flow

In the last 12 months, operating cash flow was -44.48 million and capital expenditures -29.74 million, giving a free cash flow of -74.22 million.

Operating Cash Flow	-44.48M
Capital Expenditures	-29.74M
Free Cash Flow	-74.22M
FCF Per Share	-0.21

Margins

Gross Margin	100.00%
Operating Margin	-64,031.00%
Pretax Margin	-61,438.00%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OSL:TRMED does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.08%
Shareholder Yield	-17.08%
Earnings Yield	-4.78%
FCF Yield	-6.02%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

OSL:TRMED has an Altman Z-Score of 3.77 and a Piotroski F-Score of 2.

Altman Z-Score	3.77
Piotroski F-Score	2